Adjuvant chemotherapy after esophagectomy: Is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?

• DOI: 10.1002/jso.23716
• Publication Date: 2014-06-29T16:21:21Z
• Authors: Xiao Lyu; Jing Huang; Yousheng Mao; Yutao Liu; Qinfu Feng; Kang Shao; Shugeng Gao; Yong Jiang; Jinwan Wang; Jie He
• Keywords: Esophagectomy; Taxane; Univariate analysis

Esophageal squamous cell carcinoma (ESCC) patients with regional lymph node metastases have poor prognosis after surgery. The purpose of this study was to investigate the impact various treatment modalities on survival in these patients.We retrospectively reviewed data from 349 who had undergone left transthoracic esophagectomy for thoracic ESCC January 2008 December 2010 at our institute. All lesions mid or lower third segment and pathological positive metastasis. Of patients, 143 received surgery alone, 154 underwent postoperative radiotherapy 52 taxane-based chemotherapy. Univariate multivariate Cox regression analyses were used analyze prognostic factors survival.At a median follow-up 53.1 months, 3-year OS 47.7% 44.0% adjuvant radiotherapy, 58.9% Multivariate analysis showed that therapy chemotherapy significant predictor survival.Postoperative improved compared alone. Further randomized prospective studies confirm findings are warranted.